Руководитель центра — доктор медицинских наук, профессор Бондаренко Игорь Николаевич, заведующий кафедрой онкологии и медицинской радиологии Днепропетровской медицинской академии
Профессор Бондаренко И.Н. — публикации в мировых медицинских научных изданиях

ICF

Мы стали соавторами 238 публикаций в мировых медицинских научных изданиях благодаря многолетнему опыту работы, научному интересу к клиническим исследованиям и партнерству с ведущими онкологическими центрами мира в рамках клинических исследований. Общее количество цитирований наших статей составляет 14728 раз на 14.06.2017, индекс Хирша (h-index) — 41. На сегодня, согласно рейтингу Google Scholar, проф. Бондаренко И.Н. занимает 125 место в мире среди ученых-медиков в разделе «Медицина» и 81 место в мире в разделе «Клинические исследования».

Название статьи Процитировано Год
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

C Robert, L Thomas, I Bondarenko, S O’day, J Weber, C Garbe, C Lebbe, …
New England Journal of Medicine 364 (26), 2517-2526
2731 2011
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

C Bokemeyer, I Bondarenko, A Makhson, JT Hartmann, J Aparicio, …
Journal of clinical oncology 27 (5), 663-671
1602 2008
Risk of natalizumab-associated progressive multifocal leukoencephalopathy

G Bloomgren, S Richman, C Hotermans, M Subramanyam, S Goelz, …
New England Journal of Medicine 366 (20), 1870-1880
733 2012
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancer

NJ Robert, V Diéras, J Glaspy, AM Brufsky, I Bondarenko, ON Lipatov, …
Journal of Clinical Oncology 29 (10), 1252-1260
692 2011
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study

TJ Lynch, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, …
Journal of Clinical Oncology 30 (17), 2046-2054
602 2012
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, …
New England Journal of Medicine 371 (20), 1877-1888
577 2014
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

C Bokemeyer, I Bondarenko, JT Hartmann, F De Braud, G Schuch, …
Annals of Oncology 22 (7), 1535-1546
571 2011
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, …
The lancet oncology 16 (1), 25-35
498 2015
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer

A Di Leo, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, …
Journal of Clinical Oncology 28 (30), 4594-4600
367 2010
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

SJ O’day, M Maio, V Chiarion-Sileni, TF Gajewski, H Pehamberger, …
Annals of Oncology 21 (8), 1712-1717
364 2010
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

M Reck, R Kaiser, A Mellemgaard, JY Douillard, S Orlov, M Krzakowski, …
The lancet oncology 15 (2), 143-155
359 2014
KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience

C Bokemeyer, I Bondarenko, JT Hartmann, FG De Braud, C Volovat, …
Journal of Clinical Oncology 26 (15_suppl), 4000-4000
357 2008
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non–small-cell lung cancer: final results of a phase III trial

MA Socinski, I Bondarenko, NA Karaseva, AM Makhson, I Vynnychenko, …
Journal of Clinical Oncology 30 (17), 2055-2062
321 2012
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

M Reck, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, …
Annals of Oncology 24 (1), 75-83
305 2013
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, …
The Lancet 386 (9992), 444-451
300 2015
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)

NJ Robert, V Diéras, J Glaspy, A Brufsky, I Bondarenko, O Lipatov, …
Journal of Clinical Oncology 27 (15S), 1005-1005
221 2009
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer

AC Wolff, AA Lazar, I Bondarenko, AM Garin, S Brincat, L Chow, Y Sun, …
Journal of Clinical Oncology 31 (2), 195-202
195 2012
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

KJ O’Byrne, U Gatzemeier, I Bondarenko, C Barrios, C Eschbach, …
The lancet oncology 12 (8), 795-805
186 2011
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study

J Bergh, IM Bondarenko, MR Lichinitser, A Liljegren, R Greil, NL Voytko, …
Journal of Clinical Oncology 30 (9), 921-929
176 2012
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial

RJ Motzer, D Nosov, T Eisen, I Bondarenko, V Lesovoy, O Lipatov, …
Journal of clinical oncology 31 (30), 3791-3799
168 2013
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study

C Bokemeyer, I Bondarenko, A Makhson, JT Hartmann, J Aparicio, …
Journal of Clinical Oncology 25 (18_suppl), 4035-4035
152 2007
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial

M Maio, JJ Grob, S Aamdal, I Bondarenko, C Robert, L Thomas, C Garbe, …
Journal of Clinical Oncology 33 (10), 1191-1196
151 2015
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III)

HJ Schmoll, D Cunningham, A Sobrero, CS Karapetis, P Rougier, …
Journal of Clinical Oncology 30 (29), 3588-3595
143 2012
Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)

RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, …
Cancer Research 72 (24 Supplement), S1-6-S1-6
133 2012
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

M Cristofanilli, NC Turner, I Bondarenko, J Ro, SA Im, N Masuda, …
The Lancet Oncology 17 (4), 425-439
124 2016
Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study

KJ O’byrne, I Bondarenko, C Barrios, C Eschbach, U Martens, Y Hotko, …
Journal of Clinical Oncology 27 (15S), 8007-8007
121 2009
Final overall survival: fulvestrant 500mg vs 250mg in the randomized CONFIRM trial

A Di Leo, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, …
Journal of the National Cancer Institute, djt337
115 2013
Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer

MER O’brien, MA Socinski, AY Popovich, IN Bondarenko, A Tomova, …
Journal of Thoracic Oncology 3 (7), 728-734
107 2008
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

M Aapro, H Rugo, G Rossi, G Rizzi, ME Borroni, I Bondarenko, T Sarosiek, …
Annals of oncology 25 (7), 1328-1333
106 2014
Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.

D Cunningham, NC Tebbutt, I Davidenko, AM Murad, SE Al-Batran, …
Journal of Clinical Oncology 33 (15_suppl), 4000-4000
103 2015
Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized, open-label, multicenter trial

RJ Motzer, D Nosov, T Eisen, IN Bondarenko, V Lesovoy, ON Lipatov, …
J Clin Oncol 30 (15), 277S
103 2012
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

PJ Hesketh, G Rossi, G Rizzi, M Palmas, A Alyasova, I Bondarenko, …
Annals of Oncology 25 (7), 1340-1346
98 2014
RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.

A Brufsky, I Bondarenko, V Smirnov, S Hurvitz, E Perez, O Ponomarova, …
Cancer Research 69 (24 Supplement), 42-42
98 2009
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity

E Poplin, H Wasan, L Rolfe, M Raponi, T Ikdahl, I Bondarenko, …
Journal of Clinical Oncology 31 (35), 4453-4461
95 2013
Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study

JA Sparano, AN Makhson, VF Semiglazov, SA Tjulandin, OI Balashova, …
Journal of Clinical Oncology 27 (27), 4522-4529
92 2009
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial

A Carrato, A Swieboda-Sadlej, M Staszewska-Skurczynska, R Lim, …
Journal of Clinical Oncology 31 (10), 1341-1347
84 2013
Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy

M Campone, I Bondarenko, S Brincat, Y Hotko, PN Munster, …
Annals of oncology, mdr261
62 2011
Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer (PALOMA-1; TRIO-18)

RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, …
Cancer Research 74 (19 Supplement), CT101-CT101
57 2014
Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy

I Bondarenko, OA Gladkov, R Elsaesser, A Buchner, P Bias
BMC cancer 13 (1), 386
52 2013
Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).

TJ Lynch, IN Bondarenko, A Luft, P Serwatowski, F Barlesi, RT Chacko, …
Journal of Clinical Oncology 28 (15_suppl), 7531-7531
50 2010
Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer

LWC Chow, B Xu, S Gupta, A Freyman, Y Zhao, R Abbas, MLV Van, …
British journal of cancer 108 (10), 1985-1993
41 2013
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

M Schuler, JCH Yang, K Park, JH Kim, J Bennouna, YM Chen, C Chouaid, …
Annals of Oncology 27 (3), 417-423
39 2016
Abstract S1-4: Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg

A Di Leo, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, …
Cancer Research 72 (24 Supplement), S1-4-S1-4
35 2012
Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma.

JD Wolchok, L Thomas, IN Bondarenko, S O’Day, JS Weber, C Garbe, …
Journal of Clinical Oncology 29 (18_suppl), LBA5-LBA5
35 2011
Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial.

M Reck, R Kaiser, A Mellemgaard, JY Douillard, S Orlov, MJ Krzakowski, …
Journal of Clinical Oncology 31 (18_suppl), LBA8011-LBA8011
34 2013
Anomalous aortic origin of a coronary artery: a report from the Congenital Heart Surgeons Society Registry

JA Poynter, WG Williams, S McIntyre, JA Brothers, ML Jacobs
World Journal for Pediatric and Congenital Heart Surgery 5 (1), 22-30
31 2014
Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast Cancer

NK Ibrahim, KO Yariz, I Bondarenko, A Manikhas, V Semiglazov, …
Clinical Cancer Research 17 (21), 6822-6830
31 2011
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)

S Ramalingam, G Goss, R Rosell, G Schmid-Bindert, B Zaric, Z Andric, …
Annals of Oncology 26 (8), 1741-1748
30 2015
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer

S Novello, R Kaiser, A Mellemgaard, JY Douillard, S Orlov, M Krzakowski, …
European journal of cancer 51 (3), 317-326
30 2015
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer

GV Scagliotti, I Bondarenko, F Blackhall, F Barlesi, TC Hsia, J Jassem, …
Annals of Oncology 26 (3), 497-504
29 2015
A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors

A Kellum, A Jagiello-Gruszfeld, IN Bondarenko, R Patwardhan, …
Current medical research and opinion 26 (10), 2339-2346
29 2010
The immediate results of treating patients with acute early postoperative intestinal obstruction

NM Bondarenko, IV Perets, IN Bondarenko
Klinicheskaia khirurgiia, 20-22
29 1992
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma

D Schadendorf, MM Amonkar, D Stroyakovskiy, E Levchenko, H Gogas, …
European Journal of Cancer 51 (7), 833-840
28 2015
carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)

MA Socinski, IN Bondarenko, NA Karaseva
J Clin Oncol 28 (18 Suppl)
28 2010
A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).

SS Ramalingam, GD Goss, ZG Andric, I Bondarenko, B Zaric, T Ceric, …
Journal of Clinical Oncology 31 (18_suppl), CRA8007-CRA8007
27 2013
Safety and Efficacy of Neratinib (HKI-272) in Combination with Paclitaxel in ErbB2+ Metastatic Breast Cancer.

L Chow, S Gupta, D Hershman, Z Jiang, R Epstein, I Bondarenko, …
Cancer Research 69 (24 Supplement), 5081-5081
27 2009
Analysis of the onset and resolution of immune-related adverse events during treatment with ipilimumab in patients with metastatic melanoma

C Lebbe, S O’Day, V Chiarion-Sileni, TF Gajewski, H Pehamberger, …
Perspectives in Melanoma XII, 2-4
27 2008
Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer

CP Belani, N Yamamoto, IM Bondarenko, A Poltoratskiy, S Novello, …
BMC cancer 14 (1), 290
26 2014
CONFIRM: A Phase III, Randomized, Parallel-Group Trial Comparing Fulvestrant 250 mg vs Fulvestrant 500 mg in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer.

A Di Leo, G Jerusalem, L Petruzelka, R Torres, I Bondarenko, …
Cancer Research 69 (24 Supplement), 25-25
26 2009
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)

A Awada, IN Bondarenko, J Bonneterre, E Nowara, JM Ferrero, AV Bakshi, …
Annals of oncology 25 (4), 824-831
23 2014
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study

T Eisen, Y Shparyk, N Macleod, R Jones, G Wallenstein, G Temple, …
Investigational new drugs 31 (5), 1283-1293
23 2013
Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC).

A Brufsky, RR Rivera, SA Hurvitz, IN Bondarenko, V Smirnov, V Valero, …
Journal of Clinical Oncology 28 (15_suppl), 1021-1021
23 2010
Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma

M Maio, I Bondarenko, C Robert, L Thomas, C Garbe, A Testori, H Lu, …
Asia-pacific Journal of Clinical Oncology 9, 109
22 2013
Long-term functional health status and exercise test variables for patients with pulmonary atresia with intact ventricular septum: a Congenital Heart Surgeons Society study

T Karamlou, JA Poynter, HL Walters, J Rhodes, I Bondarenko, …
The Journal of thoracic and cardiovascular surgery 145 (4), 1018-1027. e3
22 2013
Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).

MA Socinski, IN Bondarenko, NA Karaseva, A Makhson, I Vynnichenko, …
Journal of Clinical Oncology 28 (18_suppl), LBA7511-LBA7511
22 2010
Four-year survival update for metastatic melanoma (mm) patients (pts) treated with ipilimumab (ipi)+ dacarbazine (dtic) on phase 3 study CA184-024

M Maio, I Bondarenko, C Robert, L Thomas, C Garbe, A Testori, S Francis, …
Asia-pacific Journal of Clinical Oncology 8, 303
21 2012
3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase II study, OPUS

C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann, …
European Journal of Cancer Supplements 5 (4), 236
21 2007
Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial

A Awada, R Colomer, K Inoue, I Bondarenko, RA Badwe, G Demetriou, …
JAMA oncology 2 (12), 1557-1564
20 2016
Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients.

T Eisen, Y Shparyk, R Jones, NJ MacLeod, G Temple, H Finnigan, …
Journal of Clinical Oncology 31 (15_suppl), 4506-4506
20 2013
Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy

C Volovat, OA Gladkov, IM Bondarenko, S Barash, A Buchner, P Bias, …
Clinical breast cancer 14 (2), 101-108
19 2014
6079 Overall survival of patients with KRAS wild-type tumours treated with FOLFOX4±cetuximab as 1st-line treatment for metastatic colorectal cancer: The OPUS study

C Bokemeyer, I Bondarenko, JT Hartmann, F DeBraud, G Schuch, …
European Journal of Cancer Supplements 7 (2), 346
19 2009
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

JFR Robertson, IM Bondarenko, E Trishkina, M Dvorkin, L Panasci, …
The Lancet 388 (10063), 2997-3005
17 2017
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

RS Finn, JP Crown, J Ettl, M Schmidt, IM Bondarenko, I Lang, T Pinter, …
Breast Cancer Research 18 (1), 67
17 2016
Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer

J O’shaughnessy, M Campone, E Brain, P Neven, D Hayes, I Bondarenko, …
Annals of Oncology, mdv487
17 2015
Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer

P Goss, IN Bondarenko, GN Manikhas, KB Pendergrass, WH Miller Jr, …
Journal of Clinical Oncology 25 (31), 4961-4966
17 2007
Preliminary results of a phase 2 study of bosutinib (SKI-606), a dual Src/Abl kinase inhibitor, in patients with advanced breast cancer

M Campone, I Bondarenko, S Brincat, RJ Epstein, PN Munster, E Dubois, …
Breast Cancer Research and Treatment 106, S268
14 2007
Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)–positive metastatic breast cancer: a randomized clinical trial

HS Rugo, A Barve, CF Waller, M Hernandez-Bronchud, J Herson, J Yuan, …
JAMA 317 (1), 37-47
13 2017
FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18. 2 antibody, as first-line therapy in patients with advanced CLDN18. 2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.

SE Al-Batran, MH Schuler, Z Zvirbule, G Manikhas, F Lordick, A Rusyn, …
Journal of Clinical Oncology 34 (18_suppl), LBA4001-LBA4001
13 2016
Safety and efficacy of neratinib (HKI-272) in combination with paclitaxel in patients with solid tumors

L Chow, Z Jiang, R Epstein, I Bondarenko, A Awada, C Coughlin, …
Journal of Clinical Oncology 27 (15_suppl), 3557-3557
13 2009
FALCON: a phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer

MJ Ellis, I Bondarenko, E Trishkina, M Dvorkin, L Panasci, A Manikhas, …
Annals of Oncology 27 (suppl 6), LBA14_PR
12 2016
Abstract S5-07: A randomized, open-label, multicenter, phase 3 study of epoetin alfa (EPO) plus standard supportive care versus standard supportive care in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy

B Leyland-Jones, I Bondarenko, G Nemsadze, V Smirnov, I Litvin, …
Cancer Research 75 (9 Supplement), S5-07-S5-07
12* 2015
Melanoma and other skin tumors

J Sosman, M Sznol, DF McDermott, R Carvajal, DP Lawrence, …
Annals of Oncology 23 (suppl 9), ix361-ix375
12 2012
Ipilimumab plus dacarbazine in melanoma

KS Wilson, C Robert, L Thomas, I Bondarenko
N Engl J Med 365 (13), 1256
12 2011
Results of the first randomized phase II study of Cationic Liposomal Paclitaxel (EndoTAGTM-1) targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)

A Awada, IN Bondarenko, O Tarasova, J Bonneterre, E Nowara, J Ferrero, …
Ann Oncol 21 (8s), viii5
12 2010
Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin.

HS Rugo, A Barve, CF Waller, M Hernandez-Bronchud, J Herson, J Yuan, …
Journal of Clinical Oncology 34 (18_suppl), LBA503-LBA503
11 2016
A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results

T Eisen, AB Loembé, Y Shparyk, N MacLeod, RJ Jones, M Mazurkiewicz, …
British journal of cancer 113 (8), 1140-1147
11 2015
Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC).

J O’Shaughnessy, M Campone, E Brain, P Neven, DF Hayes, …
Journal of Clinical Oncology 32 (15_suppl), 519-519
11 2014
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in non-small cell lung cancer: analysis by baseline histology in a phase 2 trial

T Lynch, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, …
JOURNAL OF THORACIC ONCOLOGY 6 (6), S660-S661
11 2011
Abstract P3-14-04: Efficacy and Safety of Neratinib (HKI-272) in Combination with Paclitaxel in Her2+ Metastatic Breast Cancer

L Chow, S Gupta, DL Hershman, R Epstein, I Bondarenko, MLV Van, …
Cancer Research 70 (24 Supplement), P3-14-04-P3-14-04
11 2010
Clinical Benefit Rate and Time to Response in RIBBON-1, a Randomized, Double-Blind, Phase III Trial of Chemotherapy with or without Bevacizumab (B) for the First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC).

N Robert, V Dieras, J Glaspy, A Brufsky, I Bondarenko, O Lipatov, E Perez, …
Cancer Research 69 (24 Supplement), 6084-6084
11 2009
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL).

NH Dang, M Ogura, S Castaigne, L Fayad, M Jerkeman, JA Radford, …
Journal of Clinical Oncology 32 (15_suppl), 8529-8529
10 2014
Phase 3 study of atamestane+ toremifene vs. letrozole in advanced breast cancer

PE Goss, IN Bondarenko, GN Manikhas, KB Pendergrass, WH Miller, …
Journal of Clinical Oncology 24 (18_suppl), LBA525-LBA525
10 2006
Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells

X Niu, J Zhao, J Ma, C Xie, H Edwards, G Wang, JT Caldwell, S Xiang, …
Clinical Cancer Research 22 (17), 4440-4451
9 2016
A randomized, open-label, multicenter, phase III study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapy

B Leyland-Jones, I Bondarenko, G Nemsadze, V Smirnov, I Litvin, …
Journal of Clinical Oncology 34 (11), 1197-1207
9 2016
Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy

C Volovat, IM Bondarenko, OA Gladkov, R Elsässer, A Buchner, P Bias, …
Springerplus 4 (1), 316
9 2015
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology

SA Garnett, M Martin, G Jerusalem, L Petruzelka, R Torres, …
Breast cancer research and treatment 138 (1), 149-155
9 2013
Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial.

JH Kim, F Grossi, F De Marinis, M Cobo, JCH Yang, Y Ragulin, …
Journal of Clinical Oncology 30 (15_suppl), 7558-7558
9 2012
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

D Miles, D Cameron, I Bondarenko, L Manzyuk, JC Alcedo, RI Lopez, …
European Journal of Cancer 70, 146-155
8 2017
Survival results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.

MA Socinski, IN Bondarenko, NA Karaseva, A Makhson, I Vynnychenko, …
Journal of Clinical Oncology 29 (15_suppl), 7551-7551
8 2011
1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p) VEGF-A in patients (pts) receiving first-line paclitaxel (PAC)+/-bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC)

D Miles, D Cameron, I Bondarenko, M Lyudmila, JC Alcedo, RI Lopez, …
European Journal of Cancer 51, S287-S288
7 2015
Galaxy-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma.

SS Ramalingam, B Zaric, T Ceric, TE Ciuleanu, JF Spicer, I Bondarenko, …
Journal of Clinical Oncology 32 (15_suppl), TPS8118-TPS8118
7 2014
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in extensive disease-small cell lung cancer (ED-SCLC): Results from a phase 2 trial

M Reck, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, …
JOURNAL OF THORACIC ONCOLOGY 6 (6), S310-S311
7 2011
Final results from a randomized, double-blind, phase III study of sunitinib plus FOLFIRI vs. placebo plus FOLFIRI in first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC)

A Carrato, A Swieboda-Sadlej, M Staszewska-Skurczynska, R Lim, …
ANNALS OF ONCOLOGY 21, 19-19
7 2010
Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel

M Reck, A Mellemgaard, J von Pawel, M Gottfried, I Bondarenko, Y Cheng, …
Lung Cancer 90 (2), 267-273
6 2015
Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib+ paclitaxel vs trastuzumab+ paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).

A Awada, R Colomer, I Bondarenko, K Inoue, RA Badwe, G Demetriou, …
Journal of Clinical Oncology 33 (15_suppl), 610-610
6 2015
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

CF Waller, I Vynnychenko, I Bondarenko, Y Shparyk, JP Hodge, …
Clinical lung cancer 16 (2), 92-99
6 2015
5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)

V Dieras, J Glaspy, A Brufsky, I Bondarenko, O Lipatov, EA Perez, S Chan, …
European Journal of Cancer Supplements 7 (2), 265
6 2009
A look back at 1906—Perspectives on great earthquakes and post-earthquake investigations

DP Schwartz
Seismological Research Letters 77 (2), 123-127
6 2006
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer

W Li, J O’Shaughnessy, D Hayes, M Campone, I Bondarenko, I Zbarskaya, …
Clinical Cancer Research 22 (24), 6002-6009
5 2016
Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D).

M Reck, A Mellemgaard, SV Orlov, MJ Krzakowski, J Von Pawel, …
Journal of Clinical Oncology 32 (15_suppl), 8100-8100
5 2014
Opsalin: A phase II placebo (Pbo)-controlled randomized study of ombrabulin in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with carboplatin (Cb) and paclitaxel (P).

MJ Birrer, I Bondarenko, S Tjulandin, I Vergote, D Cibula, I Ray-Coquard, …
Journal of Clinical Oncology 31 (15_suppl), 5516-5516
5 2013
Absolute neutrophil counts in a study of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy

OA Gladkov, IM Bondarenko, R Elsaesser, A Buchner, P Bias
ANNALS OF ONCOLOGY 23, 500-500
5 2012
A randomized phase II study of axitinib in combination with pemetrexed/cisplatin (pem/cis) as first-line therapy for nonsquamous non-small cell lung cancer (NSCLC).

CP Belani, N Yamamoto, I Bondarenko, SV Orlov, J Tang, …
Journal of Clinical Oncology 30 (15_suppl), 7551-7551
5 2012
Safety of ipilimumab in patients (pts) with untreated, advanced melanoma alive beyond 2 years: Results from a phase III study.

L Thomas, JD Wolchok, C Garbe, C Lebbe, I Bondarenko, K Rodrigues, …
Journal of Clinical Oncology 30 (15_suppl), 8512-8512
5 2012
A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung cancer (NSCLC).

P Fidias, TA Ciuleanu, O Gladkov, GM Manikhas, IN Bondarenko, …
Journal of Clinical Oncology 28 (18_suppl), LBA7007-LBA7007
5 2010
Pegylated liposomal doxorubicin (PLD) plus docetaxel significantly improves time to progression (TTP) compared with docetaxel (D) monotherapy in patients with advanced breast cancer (ABC) treated with adjuvant anthracycline: results from a randomized phase 3 study.

J Sparano, A Makhson, V Semiglazov, S Tjulandin, O Balashova, …
Cancer Research 69 (2 Supplement), 80
5 2009
The opus study: Predictive value of KRAS status on clinical outcome in patients with metastatic colorectal cancer treated with either FOLFOX4 or FOLFOX4 plus cetuximas

G Schuch, I Bondarenko, J Hartmann, F De Braud, C Volovat, J Nippgen, …
ANNALS OF ONCOLOGY 19, 18-18
5 2008
Острая ранняя послеоперационная непроходимость кишечника

ИС Белый, ЛВ Усенко, ИВ Перец, ИН Бондаренко
К.: Здоров’я
5 2003
Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer

IM Bondarenko, A Ingrosso, P Bycott, S Kim, CL Cebotaru
BMC cancer 15 (1), 339
4 2015
1091PDCOMBI-D: QUALITY OF LIFE (QOL) IMPACT OF THE COMBINATION OF DABRAFENIB AND TRAMETINIB (D+ T) VERSUS DABRAFENIB MONOTHERAPY (D) IN PATIENTS WITH BRAF V600E/K UNRESECTABLE OR METASTATIC MELANOMA IN A PHASE III TRIAL

D Schadendorf, MM Amonkar, D Stroyakovskiy, E Levchenko, H Gogas, …
Annals of Oncology 25 (suppl 4), iv377-iv377
4 2014
A randomized phase II/III study of naptumomab estafenatox plus IFN-α versus IFN-α in advanced renal cell carcinoma.

RE Hawkins, ME Gore, Y Shparyk, V Bondar, O Gladkov, T Ganev, …
Journal of Clinical Oncology 31 (15_suppl), 3073-3073
4 2013
Phase I/IIb clinical trial comparing PK and safety of trastuzumab and its biosimilar candidate CT-P6

Y Im, D Krasnozhon, I Bondarenko, Z Zvirbule, K Jung, P Oliynychenko, …
Breast 22, S108-S108
4 2013
A randomized, open-label, phase 2 trial of paclitaxel/carboplatin with or without bavituximab in patients with previously untreated locally advanced or metastatic non-squamous non-small-cell lung cancer

KH Dragnev, SV Attili, R Gagua, MM Jain, I Bondarenko, J Shan
JOURNAL OF THORACIC ONCOLOGY 7 (9), S241-S242
4 2012
Four-year survival update for metastatic melanoma (MM) patients (pts) treated with ipilimumab (IPI) plus dacarbazine (DTIC) in phase III study CA184-024

M Maio, I Bondarenko, C Robert, L Thomas, C Garbe, A Testori
Ann Oncol 23 (9)
4 2012
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K–mutant melanoma: long-term survival and safety analysis of a phase 3 study

GV Long, KT Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, …
Annals of Oncology
3 2017
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma

T Ciuleanu, I Bazin, D Lungulescu, L Miron, I Bondarenko, A Deptala, …
Annals of Oncology 27 (4), 680-687
3 2016
Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies

IM Bondarenko, P Bias, A Buchner
Supportive Care in Cancer 24 (1), 267-273
3 2016
A phase iii study of balugrastim versus pegfilgrastim in breast cancer patients receiving chemotherapy with doxorubicin and docetaxel

O Gladkov, V Moiseyenko, IN Bondarenko, Y Shparyk, S Barash, L Adar, …
The oncologist 21 (1), 7-15
3 2016
Untreated metastatic diffuse gastric adenocarcinoma (DGAC): Randomized phase III study of S-1 and cisplatin vs. 5-FU and cisplatin (the DIGEST trial).

JA Ajani, M Abramov, V Bondar, I Bondarenko, YV Shparyk, V Gorbunova, …
Journal of Clinical Oncology 33 (15_suppl), 4015-4015
3 2015
Treatment outcome according to tumor ERCC1 expression status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab

C Bokemeyer, CH Koehne, I Bondarenko, A von Heydebreck, HJ Grote, …
Age 70 (70), 81
3 2013
A randomized, noninferiority study of recombinant human G-CSF/human serum albumin fusion (CG-10639) and pegfilgrastim in breast cancer patients receiving myelosuppressive therapy.

O Gladkov, V Moiseyenko, IN Bondarenko, JV Shparyk, S Barash, …
Journal of Clinical Oncology 29 (15_suppl), 9083-9083
3 2011
Способ предупреждения послеоперационной спаечной болезни брюшной полости

АБ Кутовой, ИН Бондаренко
Клин. хирургия 4, 61-63
3 1993
Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18. 2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18. 2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma

M Schuler, SE Al-Batran, Z Zvirbule, G Manikhas, F Lordick, A Rusyn, …
Annals of Oncology 27 (suppl 6), 614O
2 2016
Abstract P4-13-01: PALOMA3: Phase 3 trial of fulvestrant with or without palbociclib in pre-and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy—confirmed efficacy and safety

M Cristofanilli, I Bondarenko, J Ro, SA Im, N Masuda, M Colleoni, …
Cancer Research 76 (4 Supplement), P4-13-01-P4-13-01
2 2016
The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/HER2-metastatic breast cancer (MBC): Subanalysis from a randomized phase II study.

RS Finn, J Crown, I Lang, SO Kulyk, M Schmidt, R Patel, A Thummala, …
Journal of Clinical Oncology 33 (15_suppl), 572-572
2 2015
Veliparib (ABT-888) or placebo combined with carboplatin and paclitaxel in patients with previously untreated advanced/metastatic squamous (Sq) non-small cell lung cancer (NSCLC): A randomized phase 3 trial.

MD McKee, I Bondarenko, SZ Guclu, V Gorbunova, L Urban, P Clingan, …
Journal of Clinical Oncology 33 (15_suppl), TPS8107-TPS8107
2 2015
A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 (benefilgrastim) in Women with Breast Cancer Receiving Myelotoxic Chemotherapy

J Glaspy, T Tang, D Rutty, X Yan, I Bondarenko, D Krasnozhon
Blood 124 (21), 1584-1584
2 2014
471PEFFECT OF NINTEDANIB (BIBF 1120) COMBINED WITH STANDARD 2ND-LINE DOCETAXEL IN NSCLC PATIENTS WHO RECEIVED PRIOR PEMETREXED IN LUME-LUNG 1: A RANDOMISED, PLACEBO-CONTROLLED PHASE III TRIAL

A Mellemgaard, S Orlov, M Krzakowski, J von Pawel, M Gottfried, …
Annals of Oncology 25 (suppl 4), iv157-iv157
2 2014
473PPRIOR TAXANE USE IN THE LUME-LUNG 1 PHASE III TRIAL AND THE EFFECT ON OUTCOME FOLLOWING 2ND-LINE TREATMENT WITH NINTEDANIB (BIBF 1120) AND DOCETAXEL IN PATIENTS WITH ADVANCED NSCLC

M Krzakowski, A Mellemgaard, S Orlov, J von Pawel, M Gottfried, …
Annals of Oncology 25 (suppl 4), iv158-iv158
2 2014
Abstract P3-09-01: NEPA, a fixed-dose combination of netupitant and palonosetron, prevents chemotherapy-induced nausea and vomiting (CINV) more effectively and reduces the impact on daily living for breast cancer patients compared with palonosetron

HS Rugo, G Rossi, G Rizzi, ME Borroni, V Lorusso, M Karthaus, …
Cancer Research 73 (24 Supplement), P3-09-01-P3-09-01
2 2013
O1–030phase Ii Study Of Palbociclib (pd-0332991)+ Letrozole Vs Letrozole Alone In First-line Er+/her2-Advanced Breast Cancer

RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, J Ro, X Huang, …
Annals of Oncology 24 (suppl 9), ix32-ix33
2 2013
Overall survival (OS) and progression free survival (PFS) results for a randomized phase 2 trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIB/IV non-small cell lung cancer (NSCLC)

TJ Lynch Jr, J Neal, I Bondarenko, A Luft, P Serwatowski, F Barlesi, …
ANNALS OF ONCOLOGY 21, 126-126
2 2010
KRAS status and efficacy in the first-line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience

C Bokemeyer, I Bondarenko, J Hartmann
ASCO Annual Meeting
2 2008
CD103 and Intratumoral Immune Response in Breast Cancer

ZQ Wang, K Milne, H Derocher, JR Webb, BH Nelson, PH Watson
Clinical Cancer Research 22 (24), 6290-6297
1 2016
Claudin 18.2-a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18. 2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer

F Lordick, M Schuler, SE Al-Batran, Z Zvirbule, G Manikhas, A Rusyn, …
ANNALS OF ONCOLOGY 27
1 2016
Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients

C Volovat, I Bondarenko, O Gladkov, A Buchner, A Lammerich, U Müller, …
Supportive Care in Cancer 24 (12), 4913-4920
1 2016
Top-line results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/iv non-squamous non-small cell lung cancer

DR Spigel, I Bondarenko, G Losonczy, J Mezger, H Kalofonos, M Reck, …
Annals of Oncology 27 (suppl 6), LBA45
1 2016
A randomized phase II/III study of naptumomab estafenatox+ IFNα versus IFNα in renal cell carcinoma: final analysis with baseline biomarker subgroup and trend analysis

RE Hawkins, M Gore, Y Shparyk, V Bondar, O Gladkov, T Ganev, M Harza, …
Clinical Cancer Research 22 (13), 3172-3181
1 2016
Efficacy of Nintedanib/Docetaxel after Bevacizumab, Pemetrexed or Taxanes Therapy

D Heigener, M Reck, A Mellemgaard, S Orlov, M Krzakowski, J Von Pawel, …
JOURNAL OF THORACIC ONCOLOGY 10 (9), S323-S324
1 2015
Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy

O Gladkov, V Moiseyenko, IN Bondarenko, Y Shparyk, S Barash, L Adar, …
Medical Oncology 32 (6), 1-10
1 2015
Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: final results of a Phase 3 trial (901) and efficacy results of a second line tivozanib extension study (902)

T Hutson, D Nosov, P Tomczak, I Bondarenko, O Lipatov, CN Sternberg, …
1 2015
358pdvinflunine (vfl) plus capecitabine (cape) for advanced breast cancer (abc) previously treated with or resistant to anthracycline and resistant to taxane: a phase 3 study versus capecitabine

M Martin, Y Demidchik, I Bondarenko, I Siedakov, D Sakaeva, …
Annals of Oncology 25 (suppl 4), iv119-iv119
1 2014
Randomized, controlled, multicenter, multinational phase 2 study of docetaxel (DCT) or AXL1717 treatment in patients with squamous cell carcinoma (SCC) or adenocarcinoma (AC) of non-small cell lung cancer (NSCLC).

M Bergqvist, I Bondarenko, M Thuresson, M Klockare, J Harmenberg
Journal of Clinical Oncology 32 (15_suppl), 8091-8091
1 2014
Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI).

W Li, J O’Shaughnessy, DS Ricci, TW Griffin, TS Kheoh, MK Yu, …
Journal of Clinical Oncology 32 (15_suppl), 520-520
1 2014
Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC).

TE Ciuleanu, I Bazin, D Lungulescu, L Miron, I Bondarenko, A Deptala, …
Journal of Clinical Oncology 32 (15_suppl), 4029-4029
1 2014
Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant to anthracycline and resistant to taxane: A phase III study versus capecitabine.

MS Aapro, Y Demidchik, I Bondarenko, I Siedakov, D Sakaeva, …
Journal of Clinical Oncology 32 (15_suppl), 1013-1013
1 2014
PHASE II STUDY OF PALBOCICLIB (PD-0332991)+ LETROZOLE VS LETROZOLE ALONE IN FIRST-LINE ER+/HER2-ADVANCED BREAST CANCER

RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, J Ro, X Huang, …
ANNALS OF ONCOLOGY 24, 39-39
1 2013
Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: An integrated analysis from the phase II and phase III studies

I Bondarenko, P Bias, R Elsaesser, A Buchner
EUROPEAN JOURNAL OF CANCER 49, S443-S444
1 2013
Efficacy and safety of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy.

I Bondarenko, O Gladkov, R Elaesser, A Buchner, P Bias
Journal of Clinical Oncology 30 (15_suppl), e19587-e19587
1 2012
Hepatobiliary (HB) safety of eltrombopag administered after carboplatin+ paclitaxel (Carb+ Pac) in patients (pts) with solid tumors

A Kellum, A Jagiello-Gruszfeld, I Bondarenko, R Rafi, P Giangiulio, …
Journal of Clinical Oncology 27 (15S), e20667-e20667
1 2009
Overall Survival (OS) and New Patterns of Response in Patients (Pts) With Advanced Melanoma Treated With Ipilimumab

S O’Day, R Ibrahim, V De Pril, M Maio, VC Sileni, TF Gajewski, …
23rd Annual Meeting of the International-Society-for-Biological-Therapy-of …
1 2008
Острая послеоперационная печеночно–почечная недостаточность у хирургических больных

ВП Ужва, ИН Бондаренко
Вестн. хирургии 144 (5), 120-122
1 1990
A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.

XB Pivot, I Bondarenko, M Dvorkin, E Trishkina, JH Ahn, SA Im, …
Journal of Clinical Oncology 35 (15_suppl), 509-509
  2017
Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2–advanced breast cancer (PALOMA-1; TRIO-18).

RS Finn, J Crown, I Lang, K Boer, I Bondarenko, SO Kulyk, J Ettl, R Patel, …
Journal of Clinical Oncology 35 (15_suppl), 1001-1001
  2017
ARIEL4: An international, multicenter randomized phase 3 study of the PARP inhibitor rucaparib vs chemotherapy in germline or somatic BRCA1-or BRCA2-mutated, relapsed, high-grade ovarian carcinoma.

AM Oza, D Lorusso, A Oaknin, T Safra, E Swisher, I Bondarenko, …
Journal of Clinical Oncology 35 (15_suppl), TPS5603-TPS5603
  2017
Elsiglutide in the primary prevention of chemotherapy (CT)-induced diarrhea in patients with colorectal cancer (CRC) receiving 5-fluorouracil (5-FU)-based CT: A multinational, randomized, double-blind, placebo-controlled study.

M Karthaus, M Fedyanin, I Bondarenko, S Chessari, R Spezia, R Giorgino
Journal of Clinical Oncology 35 (15_suppl), 10101-10101
  2017
Results of bevacizumab biosimilar compared with RMP for the treatment of metastatic colorectal cancer.

EL Roca, Y Vinnyk, I Bondarenko, YV Shparyk, GM Bariani, K Abdalla, …
Journal of Clinical Oncology 35 (15_suppl), e14065-e14065
  2017
NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron

M Aapro, M Karthaus, L Schwartzberg, I Bondarenko, T Sarosiek, …
Supportive Care in Cancer 25 (4), 1127-1135
  2017
PAGE VIEWS

M Reck, D Rodríguez-Abreu, AG Robinson, A Sandler, R Gray, MC Perry, …
N Engl J Med 2017 (376), 996-997
  2017
Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer

M Bergqvist, G Holgersson, I Bondarenko, E Grechanaya, A Maximovich, …
Acta Oncologica 56 (3), 441-447
  2017
Abstract P4-22-02: Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+ TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+ C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer

V Diéras, HS Han, ME Robson, M Palácová, PK Marcom, A Jager, …
Cancer Research 77 (4 Supplement), P4-22-02-P4-22-02
  2017
Abstract S2-05: Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+ C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study

HS Han, V Diéras, ME Robson, M Palácová, PK Marcom, A Jager, …
Cancer Research 77 (4 Supplement), S2-05-S2-05
  2017
Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V plus TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer

V Dieras, HS Han, ME Robson, M Palacova, PK Marcom, A Jager, …
CANCER RESEARCH 77
  2017
111P BMI effect prognostic features of breast cancer treatments

MI Hojouj, I Bondarenko
Annals of Oncology 27 (suppl_9), mdw576. 013
  2016
220O Claudin 18.2–a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18. 2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer

F Lordick, M Schuler, SE Al-Batran, Z Zvirbule, G Manikhas, A Rusyn, …
Annals of Oncology 27 (suppl_9)
  2016
Heritage, a phase III safety and efficacy trial of the proposed trastuzumab biosimilar, Myl-1401O vs trastuzumab

H Rugo, A Barve, CF Waller, M Bronchud, J Herson, J Yuan, A Manikhas, …
Annals of Oncology 27 (suppl 6), LBA16
  2016
Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: Further analyses from the LUME-Lung 1 study

D Heigener, M Gottfried, J Bennouna, I Bondarenko, JY Douillard, …
Annals of Oncology 27 (suppl 6), 1276P
  2016
The role of tumor molecular subtypes in formation of personalized approach to the theatment of breast cancer.

IN Bondarenko, MH Elhajj, KO Chebanov, AV Phokhach, YN Bondarenko
Medical Perspectives 21 (2), 81-86
  2016
Expediency of radiation therapy and adjuvant polychemotherapy in surgical treatment of cancer.

MI Khvorostenko, IN Bondarenko, KV Barannikov, YM Khvorostenko, …
Medical Perspectives 21 (2), 77-81
  2016
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (vol 17, pg 425, 2016)

M Cristofanilli, NC Turner, I Bondarenko
LANCET ONCOLOGY 17 (4), E136-E136
  2016
The characteristics of side effects of different modes of chemotherapy for breast cancer.

IM Bondarenko, AV Phokhach
Medical Perspectives 21 (1), 23-26
  2016
Особенности побочных эффектов различных режимов химиотерапии рака молочной железы

ИН БОНДАРЕНКО, АВ ПРОХАЧ
Медичні перспективи 21 (1)
  2016
Рак молочной железы. От молекулярной биологии к персонифицированной терапии

ИН Бондаренко, МХ Эльхажж, АВ Прохач, ВФ Завизион, КО Чебанов
Морфологiя 10 (1), 18-25
  2016
ЭНДОСКОПИЯ И МАЛОИНВАЗИВ-НАЯ ХИРУРГИЯ В ДИАГНОСТИКЕ И ЛЕЧЕНИИ ПРЕДОПУХОЛЕВЫХ ЗА-БОЛЕВАНИЙ И РАКА ЖЕЛУДКА НА РАННИХ СТАДИЯХ

ИН Бондаренко, ВЕ МАШТАЛЕР, КВ БАРАННИКОВ, КО ЧЕБАНОВ, …
МОРФОЛОГIЯ 10 (1), 7-17
  2016
Peculiarities of academic motivation of the students of high medical school.

IM Bondarenko, VF Zavizion, VS Kyslytsyna, OI Aseyev, KO Dmytrenko, …
Medical Perspectives 20 (2), 17-25
  2015
Efficacy and safety of adding the retinoid tamibarotene or placebo to paclitaxel/carboplatin for advanced non-small cell lung cancer.

O Arrieta, DJ Levitt, KB Pendergrass, O Gladkov, I Bondarenko, MM Jain, …
Journal of Clinical Oncology 33 (15_suppl), e19034-e19034
  2015
Особливості навчальної мотивації у студентів вищого медичного навчального закладу

ІМ Бондаренко, ВФ Завізіон, ВС Кислицина, ОІ Асєєв, КО Дмитренко, …
Медичні перспективи 20 (2)
  2015
Peculiarities of diagnostics and clinical course of different immunohistochemical subtypes of breast cancer.

MK El Khazhzh, IM Bondarenko, OI Aseyev, IS Shponka, VF Zavizion, …
Medical Perspectives 19 (3), 29-35
  2014
Questa è la versione dell’autore dell’opera

GV Scagliotti, C Gridelli, F de Marinis, M Thomas, M Dediu, JL Pujol, …
Lung Cancer 85 (3), 408-14
  2014
1494PSAFETY AND TOLERABILITY OF LIPEGFILGRASTIM (LIPEG) AND PEGFILGRASTIM (PEG) IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY (CTX): AN INTEGRATED ANALYSIS OF 2 STUDIES STRATIFIED BY AGE

IM Bondarenko, P Bias, U Müller, A Buchner
Annals of Oncology 25 (suppl 4), iv522-iv522
  2014
ANTIANGIOGENIC-SPECIFIC ADVERSE EVENTS (AES) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NINTEDANIB (N) AND DOCETAXEL (D)

A Mellemgaard, M Reck, S Orlov, M Krzakowski, J Von Pawel, M Gottfried, …
JOURNAL OF THORACIC ONCOLOGY 9 (9), S155-S155
  2014
PATIENT-REPORTED OUTCOMES FROM THE LUME-LUNG 1 TRIAL: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY IN SECOND-LINE ADVANCED NSCLC PATIENTS

A Mellemgaard, JY Douillard, S Novello, R Kaiser, S Orlov, M Krzakowski, …
JOURNAL OF THORACIC ONCOLOGY 9 (9), S152-S153
  2014
30 Nintedanib (BIBF 1120)+ docetaxel as second-line therapy in patients with stage IIIB/IV or recurrent NSCLC: results of the phase III, randomised, double-blind LUME-Lung 1 trial

M Reck, A Mellemgaard, JY Douillard, S Orlov, M Krzakowski, …
Lung Cancer 83, S12
  2014
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

M Mandalà, M Millward, A Arance, I Bondarenko, J Haanen, …
  2014
C148: Partial versus radical nephrectomy: Analyses of the perioperative complications

S Styopushkin, I Bondarenko, K Chebanov, R Sokolenko, V Chaikovkyi
European Urology Supplements 6 (13), e1331, e1331a
  2014
Особливості діагностики та клінічного перебігу різних імуногістохімічних підтипів раку молочної залози

ЕЛЬХ МХ, ІМ Бондаренко, ОІ Асєєв, ІС Шпонька, ВФ Завізіон, АС Скляр, …
Медичні перспективи 19 (3)
  2014
Evaluation Of Electrocardiogram Parameters In Patients With Breast and Lung Cancer Treated With Chemotherapy and Lipegfilgrastim Or Pegfilgrastim

A Lammerich, I Bondarenko
Blood 122 (21), 4856-4856
  2013
ANALYSIS OF PATIENT-REPORTED OUTCOMES FROM THE LUME-LUNG 1 TRIAL: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY IN SECOND-LINE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS

S Novello, A Mellemgaard, R Kaiser, JY Douillard, S Orlov, M Krzakowski, …
JOURNAL OF THORACIC ONCOLOGY 8, S1207-S1207
  2013
PO120 FACTORS AFFECTING CHANGES IN IMMUNOHISTOCHEMISTRY PHENOTYPE OF BREAST CANCER

O Aseyev, I Bondarenko, M El Hajj, V Zavizion, A Kunnik
The Breast 22, S60
  2013
Somatoform disorders in the family doctor’s practice.

V Prykhodko, I Mikropulo, M Oleinik, E Kononenko, D Moreva, O Gogol, …
Medical Perspectives 18 (3), 15-24
  2013
Incidence of bone pain in patients with breast cancer treated with balugrastim or pegfilgrastim: An integrated analysis from the phase II and III studies

O Gladkov, C Volovat, A Buchner, S Barash, H Voliovitch, T Erez, N Lang, …
EUROPEAN JOURNAL OF CANCER 49, S439-S439
  2013
Analysis of ANC recovery from a Phase III study of lipegfilgrastim versus pegfilgrastim in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy

I Bondarenko, P Bias, R Elsaesser, A Buchner
EUROPEAN JOURNAL OF CANCER 49, S434-S435
  2013
Ganetespib in combination with docetaxel versus docetaxel alone in second line adenocarcinoma patients with KRAS mutations and elevated LDH levels

DA Fennell, GD Goss, Z Andric, I Bondarenko, B Zaric, T Ceric, …
EUROPEAN JOURNAL OF CANCER 49, S801-S801
  2013
реДКИй КЛИнИЧеСКИй СЛуЧАй: зернИСто-КЛетоЧнАя МИоБЛАСтоМА (оПуХоЛь АБрИКоСовА) МоЛоЧной жеЛезы

VF Zavizion, IM Bondarenko, IV Bilenky, VA Gurtovyy, OI Aseyev, …
ББК 55.6 ISSN 2307-1575 Отв. секретар–Смирнов ВМ Секретаріат: Золотухин СЄ …
  2013
Вплив системного лікування на імунофенотип раку молочної залози

МХ Ельхажж, ІМ Бондаренко, ВФ Завізіон, АВ Куник, ОІ Асєєв
Університетська клініка, 54-58
  2013
Supportive care

S Clarke, C Tan, J Read, V Phan, JK Peat, P Beale, Y Gornadha, …
Annals of Oncology 23 (suppl 9), ix499-ix527
  2012
Effects of nintedanib (BIBF 1120) on QTc interval in previously untreated patients with renal cell cancer (RCC): Results from an open-label, phase II study.

T Eisen, Y Shparyk, NJ MacLeod, G Wallenstein, G Temple, Y Khder, …
Journal of Clinical Oncology 30 (15_suppl), e15037-e15037
  2012
Tumor Microenvironment

TJ Lynch, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko
J Clin Oncol
  2012
Сучасні підходи до викладання онкології як основа вдосконалення навчального процесу

ВФ Завізіон, ІМ Бондаренко
Медичні перспективи 17 (1)
  2012
A NEW METHOD OF MULTIMODALITY TREATINENT OF LOCALLY ADVANCED CANCER OF THE FLOOR OF THE ORAL CAVITY

MP Komskyi, IN Bondarenko, NV Gutorova, OV Kolesnik, KA Kochet
БУКОВИНСЬКИЙ МЕДИЧНИЙ ВІСНИК, 210
  2012
P3-17-06: Final Results of a Controlled, Randomized 3-Arm Phase II Trial of EndoTAG”-1, a Cationic Liposomal Formulation of Paclitaxel Targeting Tumor Endothelial Cells, in Advanced Triple-Negative Breast Cancer (TNBC).

A Awada, IN Bondarenko, O Tarasova, J Bonneterre, E Nowara, …
Cancer Research 71 (24 Supplement), P3-17-06-P3-17-06
  2011
A Second Randomised Ipilimumab Phase Iii Trial Shows Significant Survival Improvement In Metastatic Melanoma

P Hersey, JD Wolchock, L Thomas, IN Bondarenko, S O’day, J Weber, …
Asia-pacific Journal of Clinical Oncology 7, 111
  2011
Application of new methodology to allow comparison of duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial

S Garnett, M Martin, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, …
The Breast 20, S45
  2011
5079 POSTER The Substantiation of Optimal Approaches to Systemic Treatment for Patients With Metastatic Breast Cancer

O Asevev, K Dmytrenko, I Bondarenko, V Kyslytsyna, V Mashtaler
European Journal of Cancer 47, S354
  2011
PAGE VIEWS

C Robert, L Thomas, I Bondarenko, FS Hodi, SJ O’Day, DF McDermott
N Engl J Med 2011 (365), 1256-1258
  2011
NAB-PACLITAXEL AND CARBOPLATIN COMPARED WITH CREMOPHOR-BASED PACLITAXEL AND CARBOPLATIN IS EFFECTIVE AND SAFE AS FIRST-LINE THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER: FINAL RESULTS OF A PHASE 3 STUDY

MA Socinski, I Bondarenko, N Karaseva, A Makhson, I Vynnychenko, …
JOURNAL OF THORACIC ONCOLOGY 6 (6), S417-S417
  2011
PREDICTING ENDOCRINE THERAPY EFFICACY IN MENOPAUSAL PATIENTS WITH LUMINAL-TYPE ADVANCED BREAST CANCER

O Aseyev, I Bondarenko
ANNALS OF ONCOLOGY 22, 64-64
  2011
mAyo CliniC CARdiology UpdATE 2012

C Robert, L Thomas, I Bondarenko
N Engl J Med 364, 2517-26
  2011
Економічна оцінка протипухлинної терапії метастатичного раку легенів та її ускладнень на прикладі клінічної ситуації

ОВ Зайцева, ВФ Завізіон, ІМ Бондаренко, ОВ Макаренко
Фармакологія та лікарська токсикологія, 21
  2011
Overall Survival and Progression Free Survival Results for a Randomized Phase 2 Trial of Ipilimumab (IPI) and Paclitaxel/Carboplatin (P/C) in First-Line Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

T Lynch, J Neal, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, …
JOURNAL OF THORACIC ONCOLOGY 5 (12), S515-S515
  2010
FIRST LINE SYSTEM THERAPY INDIVIDUALIZATION IN POSTMENOPAUSAL PATIENTS WITH LUMINAL SUBTYPE OF ADVANCED BREAST CANCER

O Aseyev, IN Bondarenko
ANNALS OF ONCOLOGY 21, 43-44
  2010
476 PFS by patient subgroup for standard chemotherapies in combination with bevacizumab (BV) in the first-line treatment of HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results from RIBBON-1

I Bondarenko, J Glaspy, A Brufsky, O Lipatov, EA Perez, S Chan, X Zou, …
European Journal of Cancer Supplements 8 (3), 198
  2010
496 RIBBON-1: efficacy of capecitabine-bevacizumab in patients with triple-negative metastatic breast cancer (MBC)

H Lindman, O Lipatov, I Bondarenko, L Panasci, R Coleman
European Journal of Cancer Supplements 8 (3), 204
  2010
Botargues J. vi82 (P-0190) Boucça-Machado T. vi90 (P-0218), vi92 (P-0225), vi92 (P-0227) Bouché O. vi51 (P-0078) Bouillet P. vi104 (P-0271)

F Boissiere-Michot, I Bondarenko, F Bosman
  2010
Hepatobiliary (HB) safety of eltrombopag administered after carboplatin plus paclitaxel (Carb plus Pac) in patients (pts) with solid tumors

A Kellum, A Jagiello-Gruszfeld, I Bondarenko, R Rafi, P Giangiulio, …
JOURNAL OF CLINICAL ONCOLOGY 27 (15)
  2009
Impact of pegylated liposomal doxorubicin (PLD) plus docetaxel (D) versus single-agent D on health-related quality of life (HRQOL) of patients with advanced breast cancer (BC) previously treated with neoadjuvant-adjuvant anthracycline

SA Tjulandin, IN Bondarenko, VF Semiglazov, OI Balashova, …
Journal of Clinical Oncology 27 (15_suppl), e20522-e20522
  2009
Weekly paclitaxel in women with metastatic breast cancer

I Bondarenko, K Dmytrenko, V Kyslytsyna
ANNALS OF ONCOLOGY 19, 133-134
  2008
Use of neural networks to forecast efficiency of systemic therapy of advanced breast cancer in menopausal patients

O Aseyev, I Bondarenko
ANNALS OF ONCOLOGY 19, 133-133
  2008
Phase 3 study of atamestane plus toremifene vs. letrozole in advanced breast cancer

PE Goss, IN Bondarenko, GN Manikhas, KB Pendergrass, WH Miller, …
JOURNAL OF CLINICAL ONCOLOGY 24 (18), 932S-932S
  2006
Toremifene in the treatment of metastatic melanoma

S Azatyan, N Zaliznyak, I Bondarenko
ANNALS OF ONCOLOGY 17, 165-165
  2006
Ways of optimization for the plan of treatment of acute appendicitis

NM Bondarenko, AI Novikov, IN Bondarenko
Klinichna khirurhiia/Ministerstvo okhorony zdorov’ia Ukraïny, Naukove …
  2003
The possibilities of application of iodinedicerinum in urgent surgery

AI Novikov, GM Larionov, AK Iarosh, SA Tylik, TM Solov’evskaia, …
Klinichna khirurhiia, 46
  2000
Correction to Lancet Oncol

M Cristofanilli, NC Turner, I Bondarenko
 
2012 ТОМ XVII № 44

ВІ Жилюк, ВЙ Мамчур, ОГ Родинський, ОГ Зінов’єва, АВ Самойленко, …
 
2014 ТОМ XIX № 33

ЕМ Білецька, НМ Онул, ОГ Родинський, ЮВ Козлова, ВО Галаган, …
 
Науковий журнал Дніпропетровської державної медичної академії

ОГ Родинський, ВА Гузь, ЛВ Гузь, ОМ Литвинова, АВ Шарун, …
 
71 Radical-Intent Hypofractionated Radiotherapy for Locally Advanced NoneSmall-Cell Lung Cancer: A Systematic Review of the Literature Tyler S. Kaster, Brian Yaremko, David A. Palma, George B. Rodrigues 80 Standard Treatment Option in Stage III NoneSmall-Cell Lung Cancer: Case Against Trimodal Therapy and Consolidation Drug Therapy

B Jeremic, S Li, X Qi, Y Huang, D Liu, F Zhou, C Zhou, CF Waller, …
 
RIBBON-1: efficacy of capecitabine plus bevacizumab in patients with triple-negative metastatic breast cancer

H Lindman, O Lipatov, I Bondarenko, L Panasci, R Coleman
Age 462 (153), 65
 
SOCIALICON
SOCIALICON
Facebook
Google+
Twitter
YouTube